Last year, we could have saved 100 million francs by using more biosimilar drugs. This is what reveals a study commissioned by the association of sickness funds Curafutura and by the umbrella organizations Intergenerika and Biosimilar.ch. In question, bad incentives that would be to remove as quickly as possible in the distribution. This publication comes as the Council of States’ Health Commission is preparing to start its work on the Federal Council’s reform project in favor of a reference price for medicines.
Expensive treatments
In 2020, drug spending continued to increase. They amounted to 7.3 billion at the expense of basic insurance, an increase of 4% equivalent to 300 million. However, nearly three quarters of this increase is due to the treatment of cancerous and autoimmune diseases, for which we know that the bill oscillates between 15,000 and 25,000 francs on average per patient and per year. This is where increased use of biosimilars would help curb rising health care costs.
Get the latest news delivered to your inbox
Follow us on social media networks
